Update on Reproxalap PDUFA Timing episode artwork

EPISODE · Dec 17, 2025 · 8 MIN

Update on Reproxalap PDUFA Timing

from Eyewire News: The Podcast · host Eyewire News

Aldeyra provides an update on the timing of its dry eye disease treatment candidate reproxalap; Ocular Therapeutix pursues an accelerated NDA pathway for wet AMD therapy Axpaxli; and companies with late-stage drug candidates announce FDA submission plans.  Learn more about your ad choices. Visit megaphone.fm/adchoices

NOW PLAYING

Update on Reproxalap PDUFA Timing

0:00 8:51

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Eyewire News: The Podcast?

This episode is 8 minutes long.

When was this Eyewire News: The Podcast episode published?

This episode was published on December 17, 2025.

What is this episode about?

Aldeyra provides an update on the timing of its dry eye disease treatment candidate reproxalap; Ocular Therapeutix pursues an accelerated NDA pathway for wet AMD therapy Axpaxli; and companies with late-stage drug candidates announce FDA submission...

Can I download this Eyewire News: The Podcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!